SMA Newsroom

Dec 20, 2024

Community Update Biohaven: RESILIENT Letter to SMA Community

Biohaven released the results from their RESILIENT SMA clinical trial, and they did not meet the primary endpoint. Biohaven is currently analysing the data further and is engaging in discussion with Health Authorities. 

In the meantime, taldefgrobep (the study drug) will continue to be provided to the study participants.

This website stores essential cookies to enable important site functionality, and analytics cookies so we can understand usage and improve the service. Read our privacy policy